Publications by authors named "Wendi Xuzhang"
Article Synopsis
- Combination therapy using platinum-based chemotherapy and PD-L1 inhibitors significantly improves survival rates for small-cell lung cancer (SCLC) patients compared to single anti-PD-L1 therapy.
- A positive correlation was found between the expression of a protein called Gasdermin E (GSDME) and patient survival, with high GSDME levels making SCLC cells more sensitive to treatment.
- Cisplatin activates GSDME, leading to the release of immune-boosting cytokines that enhance the effectiveness of anti-PD-L1 therapy, suggesting that GSDME could be a key biomarker and target for improving patient responses to treatment.
Major pathologic remission (MPR, residual tumor <10%) is a promising clinical endpoint for prognosis analysis in patients with lung cancer receiving pre-operative PD-1 blockade therapy. Most of the current biomarkers for predicting MPR such as PD-L1 and tumor mutation burden (TMB) need to be obtained invasively. They cannot overcome the spatiotemporal heterogeneity or provide dynamic monitoring solutions.
View Article and Find Full Text PDFBackground: Oligoprogressive disease is recognized as the overall umbrella term; however, a small number of progressions on imaging can represent different clinical scenarios. This study aims to explore the optimal treatment strategy after immunotherapy (IO) resistance in advanced non-small-cell lung cancer (NSCLC), especially in personalized therapies for patients with different oligoprogressive patterns.
Methods: Based on European Society for Radiotherapy and Oncology/European Organization for Research and Treatment of Cancer consensus, metastatic NSCLC patients with cancer progression after IO resistance were divided into four patterns, repeat oligoprogression (REO, oligoprogression with a history of oligometastatic disease), induced oligoprogression (INO, oligoprogression with a history of polymetastatic disease), de-novo polyprogression (DNP, polyprogression with a history of oligometastatic disease), and repeat polyprogression (REP, polyprogression with a history of polymetastatic disease).